Skip to main content
Caplight Logo









Bionoxx Inc.

Bionoxx Inc.

Private
South KoreaHealthcare & Life Scienceshttp://bionoxx.com/

Last Round

Series B

Mar 21, 2023

Total Funding Raised

$17.26M

Company Overview

Bionoxx Inc. is a biotechnology company that develops neutrophil-directed T cell modulation technology to fight cancer and immune disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

oncolytic virus therapyimmuno-oncologycancer immunotherapysolid tumor treatmentT cell modulationcheckpoint inhibitor resistanceCAR-T cell therapycancer-killing virusclinical-stage biotechimmune modulationautologous cell therapyneutrophil modulationpersonalized immune modulation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bionoxx Inc. Comparables

Compare Bionoxx Inc. with similar companies based on industry and business-model similarity.

Bionoxx Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SillaJen Inc
81%
VacV Biotherapeutics
80%
KaliVir Immunotherapeutics
80%

Bionoxx Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 21, 2023
Series BApr 1, 2019

Bionoxx Inc. Investors

Notable investors and investment history

Bionoxx Inc. investors
InvestorRounds
DA Value InvestmentSeries B
ROI Investment PartnersSeries B
Yuanta InvestmentSeries B
ID VenturesSeries B
Daekyo InvestmentSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 27, 2024

    Grew 36% QoQ, from 11 to 15 employees.

  • Oct 20, 2024

    Grew 27% QoQ, from 11 to 14 employees.

Bionoxx Inc. Filings

Explore SEC and related filing metadata, where available.

Bionoxx Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Bionoxx Inc.'s valuation, stock price, and market status.

Is Bionoxx Inc. a public or private company?

Bionoxx Inc. is a private company.

What is the current stock price of Bionoxx Inc.?

Bionoxx Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Bionoxx Inc. worth (valuation)?

Valuation information for Bionoxx Inc. is not publicly available.

Can I buy Bionoxx Inc. stock?

Bionoxx Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Bionoxx Inc.'s last funding round?

Bionoxx Inc.'s most recent funding round was Series B on March 21, 2023.

Who are the main investors in Bionoxx Inc.?

Key investors in Bionoxx Inc. include Yuanta Investment, Daekyo Investment.

Will Bionoxx Inc. IPO soon?

No public IPO plans have been announced for Bionoxx Inc..

How can I track Bionoxx Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Bionoxx Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSouth Korea
Employee Range11
Year Founded2016
Last FundingMar 21, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?